Twin Capital Management Inc. Lowers Holdings in Pfizer Inc. (NYSE:PFE)

Twin Capital Management Inc. decreased its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 131,753 shares of the biopharmaceutical company’s stock after selling 3,591 shares during the quarter. Twin Capital Management Inc.’s holdings in Pfizer were worth $3,793,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the stock. RB Capital Management LLC grew its holdings in Pfizer by 6.7% during the first quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company’s stock valued at $282,000 after purchasing an additional 341 shares during the period. Ironwood Wealth Management LLC. lifted its position in shares of Pfizer by 1.1% in the first quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company’s stock valued at $1,868,000 after acquiring an additional 400 shares in the last quarter. United Bank lifted its position in shares of Pfizer by 0.6% in the first quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock valued at $2,416,000 after acquiring an additional 290 shares in the last quarter. Ergoteles LLC lifted its position in shares of Pfizer by 136.3% in the first quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company’s stock valued at $1,903,000 after acquiring an additional 21,209 shares in the last quarter. Finally, Mackenzie Financial Corp lifted its position in shares of Pfizer by 6.4% in the first quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company’s stock valued at $69,238,000 after acquiring an additional 79,887 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Guggenheim assumed coverage on Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective on the stock. TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research report on Thursday, January 4th. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Monday. Twelve investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, Pfizer currently has a consensus rating of “Hold” and a consensus target price of $36.88.

Pfizer Trading Down 0.6 %

NYSE:PFE traded down $0.15 during midday trading on Thursday, hitting $25.27. The stock had a trading volume of 20,581,875 shares, compared to its average volume of 42,262,844. Pfizer Inc. has a one year low of $25.25 and a one year high of $40.56. The company has a market capitalization of $143.09 billion, a price-to-earnings ratio of 70.61, a PEG ratio of 1.16 and a beta of 0.61. The stock has a 50-day moving average of $27.19 and a 200 day moving average of $28.76. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. During the same quarter in the prior year, the firm earned $1.14 earnings per share. Pfizer’s revenue was down 41.3% compared to the same quarter last year. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.24 EPS for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.